Clinical trial
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
NCT00269412 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2005
- Completion date
- September 30, 2008
- Enrollment
- 525 (estimated)
- Sites
- 67
Conditions
As the registry lists them; a condition with its own page is linked.